Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Mechanism BTN2A1 modulators(Butyrophilin subfamily 2 member A1 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | NL | 05 Jan 2023 |